<p>The acquisition bolsters PolyPeptide Laboratories' manufacturing capacity and capabilities, from small-scale custom peptides for research to large-scale peptides for therapeutic applications. Such capabilities complement the group's long-established core strength in GMP manufacturing, and will help service a range of projects from conception through commercialization. <br /><br />With the NeoMPS acquisition, PolyPeptide Laboratories Group operates GMP facilities in the US (Torrance and San Diego, California), France (Strasbourg), Denmark (Hillerod) and Sweden (Malmo). Ongoing expansions in Malmo, Torrance, and Strasbourg are continuing as planned. The group is also constructing a soon-to-be-launched GMP facility in Mumbai, India that will be focused on generic peptides. <br /><br />Jane Salik, CEO of PolyPeptide Laboratories Group, said: The addition of NeoMPS to the PolyPeptide Laboratories Group is a great fit, and offers customers of both companies an even more comprehensive range of services for every stage of development. With this acquisition, we are expanding our capacity to meet the needs of customers who demand the most robust, scalable and cost efficient peptide manufacturing available.</p>